Myeloma Paper of the Day, August 11th, Suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
US Myeloma Immunotherapy Consortium real-world experience with teclistamab for relapsed/refractory myeloma shows ≥PR 53%, ≥VGPR 45%, median PFS 5.8 mos, 12-mo OS 61%, CRS 54%, ICANS 11% (2.2% grade ≥3), infections 42%.”
Title: Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Authors: Beatrice M. Razzo, Shonali Midha, Andrew J. Portuguese, Ariel F. Grajales-Cruz, Andre De Menezes Silva Corraes, Patrick Costello, Yuxin Liu, Adam S. Sperling, Omar Nadeem, Danai Dima, Rahul Banerjee, Andrew J. Cowan, Aimaz Afrough, Larry D. Anderson, Alex Lieberman-Cribbin, Gurbakhash Kaur, Anmol Goyal, Shebli Atrash, Christopher J. Ferreri, Peter M. Voorhees, Oren Pasvolsky, Hans C. Lee, Krina K. Patel, Kelley L. Julian, Peter A. Forsberg, Megan M. Herr, Saurabh Chhabra, Ricardo D. Parrondo, Yi Lin, Anna Chen, Sandra P. Susanibar-Adaniya, Jack Khouri, Shahzad Raza, Faiz Anwer, Mariola Vazquez-Martinez, Omar Castaneda Puglianini, Douglas W. Sborov, James A. Davis, Adriana Rossi, Leyla Shune, Jenny Bhurtel, Wei-Ting Hwang, Doris K. Hansen, Surbhi Sidana, Alfred L. Garfall, Shambavi Richard
You can read the Full Article on Blood Cancer Discovery.
You can find more posts featuring Robert Orlowski on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023